Diphenylether

Diphenylether

SCHEMBL308323

C=CC.C=CC.CC(O)CO.COC.OCCO.c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Diphenylether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
LTA4H P09960 5/20 0.41
NPY5R Q15761 5/20 0.40
TSHR P16473 1/20 0.39
KDM4E B2RXH2 2/20 0.36
TGM2 P21980 1/20 0.36
PTGS1 P23219 1/20 0.36
NR1H2 P55055 1/20 0.36
BAX Q07812 1/20 0.36
RAB9A P51151 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylether SCHEMBL5275954 0.86 LTA4H (0.52) LTA4HTSHRTGM2NR1H2BAX
Diphenylether SCHEMBL896406 0.86 LTA4H (0.52) LTA4HTSHRTGM2NR1H2BAX
Diphenylether SCHEMBL1001110 0.86 LTA4H (0.52) LTA4HTSHRTGM2NR1H2BAX
Diphenylether SCHEMBL50452 0.84 LMNA (0.57) LMNALTA4HNPY5RTSHRKDM4E
Diphenylether SCHEMBL28593325 0.82 LMNA (0.55) LMNALTA4HNPY5RTSHRKDM4E
Diphenylether SCHEMBL23494789 0.82 TGM2 (0.47) LMNALTA4HNPY5RKDM4ETGM2
Diphenylether SCHEMBL8049569 0.81 LMNA (0.53) LMNALTA4HNPY5RTSHRKDM4E
Phenoxyethanol SCHEMBL11600631 0.81 ALDH1A1 (0.61) LMNAKDM4ERAB9ATDP1GAA
Propylene Glycol SCHEMBL21060833 0.80 TDP1 (0.50) TSHRTDP1
Diphenylether SCHEMBL3797141 0.80 LTA4H (0.47) LMNALTA4HNPY5RTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976362-B1 METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2023-06-07 EP claimed
US-11584097-B2 Method for making opaque colored silicone hydrogel contact lenses ALCON INC. (CH) 2023-02-21 US claimed
US-20200376787-A1 METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2020-12-03 US claimed
WO-2020240440-A1 METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2020-12-03 WO claimed
US-9244195-B2 Silicone hydrogel lenses with nano-textured surfaces NOVARTIS AG (CH) 2016-01-26 US claimed
EP-2718751-B1 SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES NOVARTIS AG (CH) 2015-07-22 EP claimed
EP-2718751-A1 SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES Novartis AG (CH) 2014-04-16 EP claimed
US-8506856-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2013-08-13 US claimed
WO-2012170603-A1 SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES NOVARTIS AG (CH) 2012-12-13 WO claimed
US-20120314185-A1 SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES ALCON INC. (CH) 2012-12-13 US claimed
CN-101896837-A Method of making silicone hydrogel contact lenses NOVARTIS AG 2010-11-24 CN claimed
EP-2232304-A2 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES Novartis AG (CH) 2010-09-29 EP claimed
WO-2009076143-A2 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES NOVARTIS AG (CH) 2009-06-18 WO claimed
US-20090146330-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2009-06-11 US claimed
EP-4121802-B1 HIGH REFRACTIVE INDEX SILOXANE INSERT MATERIALS FOR EMBEDDED CONTACT LENSES ALCON INC (CH) 2024-07-17 EP disclosed
EP-4121279-B1 METHOD FOR PRODUCING EMBEDDED OR HYBRID HYDROGEL CONTACT LENSES ALCON INC (CH) 2024-07-10 EP disclosed
EP-3724696-B1 WEEKLY AND MONTHLY DISPOSABLE WATER GRADIENT CONTACT LENSES ALCON INC (CH) 2024-07-03 EP disclosed
US-20030125498-A1 Biomedical devices containing internal wetting agents JOHNSON & JOHNSON VISION CARE, INC. 2003-07-03 US disclosed
WO-2003022321-A2 BIOMEDICAL DEVICES CONTAINING INTERNAL WETTING AGENTS JOHNSON & JOHNSON VISION CARE, INC. (US) 2003-03-20 WO disclosed
WO-2003022322-A2 BIOMEDICAL DEVICES CONTAINING INTERNAL WETTING AGENTS JOHNSON & JOHNSON VISION CARE, INC. (US) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584097-B2 Method for making opaque colored silicone hydrogel contact lenses COIL, CRYAB, CRYAA LMNA 613/4885LTA4H 206/4885NPY5R 4211/4885
US-20200376787-A1 METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES COIL, CRYAB, CRYAA LMNA 613/4885LTA4H 206/4885NPY5R 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.